^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TBI-1501

    i
    Other names: CD19 chimeric antigen receptor T cell therapy , CD19-CAR gene therapy, CD19-CAR T cell therapy, TBI-1501
    Associations

    News

    Trials
    Company:
    Jichi Medical University, Otsuka, Takara
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=21, Active, not recruiting, Takara Bio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • TBI-1501
    over3years
    Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=21, Recruiting, Takara Bio Inc. | Trial completion date: Mar 2020 --> Mar 2035 | Trial primary completion date: Mar 2019 --> Mar 2035
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    TBI-1501